Cargando…
Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome
OBJECTIVE: The European Increlex(®) Growth Forum Database Registry monitors the effectiveness and safety of recombinant human insulin-like growth factor-1 (rhIGF1; mecasermin, Increlex(®)) therapy in patients with severe primary IGF1 deficiency (SPIGFD). We present data from patients with and withou...
Autores principales: | Bang, Peter, Woelfle, Joachim, Perrot, Valerie, Sert, Caroline, Polak, Michel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849377/ https://www.ncbi.nlm.nih.gov/pubmed/33434161 http://dx.doi.org/10.1530/EJE-20-0325 |
Ejemplares similares
-
Pubertal Timing and Growth Dynamics in Children With Severe Primary IGF-1 Deficiency: Results From the European Increlex(®) Growth Forum Database Registry
por: Bang, Peter, et al.
Publicado: (2022) -
Assessment of compatibility of rhIGF-1/rhIGFBP-3 with neonatal intravenous medications
por: Salamat-Miller, Nazila, et al.
Publicado: (2022) -
rhIGF-1 Therapy: A Silver Bullet for Bronchopulmonary Dysplasia
Prevention?
por: Plosa, Erin J., et al.
Publicado: (2020) -
rhIGF-1/rhIGFBP-3 in Preterm Infants: A Phase 2 Randomized Controlled Trial
por: Ley, David, et al.
Publicado: (2018) -
Pilot dose-ranging of rhIGF-1/rhIGFBP-3 in a preterm lamb model of evolving bronchopulmonary dysplasia
por: Albertine, Kurt H., et al.
Publicado: (2023)